NFE2L2 and clear cell renal carcinoma: Similarly, DPP9 disrupts KEAP1‐NRF2 binding through its conserved ESGE motif, leading to NRF2‐dependent transcriptional activation of SLC7A11 and promoting tumorigenesis and drug resistance in renal clear cell carcinoma [54].